Answers are grounded in this paper and cite their sources.
Introduction Dry eye disease (DED) disproportionately affects postmenopausal women, yet the role of hormone replacement therapy (HRT) remains unclear. This systematic review of seven randomized controlled trials (RCTs) and two prospective nonrandomized cohort studies evaluates the efficacy of systemic and topical HRT on DED outcomes.Methods We conducted a PRISMA-guided systematic review and meta-analysis assessing standardized HRT formulations (estrogen-only, estrogen-progesterone, or progesterone-only) in postmenopausal women. Comparators included a placebo or no treatment. Primary outcomes included tear breakup time (TBUT), Schirmer test scores, intraocular pressure (IOP), and DED symptoms. Premenopausal participants or significant ocular/systemic comorbidities were excluded.Results 594 participants from nine studies met inclusion criteria. Participants utilizing HRT showed no significant improvement in TBUT, Schirmer scores, or symptoms, with moderate to high heterogeneity (I2 = 40–95%). Confidence intervals crossed zero for all primary outcomes. Tear breakup time (n = 343) and Schirmer scores (n = 465) yielded standardized mean differences (SMDs) of 0.03 and -0.17, respectively. Symptom-based outcomes, including foreign body sensation (mean difference [MD] -4.83) and dryness (MD 0.47), were similarly null.Conclusions Despite biologic plausibility, current data does not support routine HRT for DED management in postmenopausal women. Heterogeneity highlights the need for standardized trial designs.
No takes yet. Share an insight, caveat, or question.
George et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: